Linagliptin Pharos

Linagliptin, the active ingredient in Linagliptin Pharos, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving glycemic control.

GNH USA supplies Linagliptin Pharos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin acts on the dipeptidyl peptidase‑4 pathway to manage hyperglycaemia in type 2 diabetes.

- Type 2 diabetes mellitus (monotherapy): improves blood glucose levels when used alone with diet and exercise. - Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin, sulfonylureas or insulin. - Patients with renal impairment: can be used without dose adjustment, providing an option for those with reduced kidney function.

Linagliptin may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain of mild to moderate intensity. - Upper respiratory tract infection: symptoms such as cough and congestion. - Dizziness: occasional sensation of light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes requiring immediate medical attention. - Severe hypersensitivity reactions: including rash, angioedema or anaphylaxis. - Bullous pemphigoid: rare skin disorder characterised by blistering lesions. - Hepatic injury: marked elevation of liver enzymes or jaundice.

Before initiating Linagliptin, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: monitor kidney function, although dose adjustment is not required. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Cardiovascular disease: assess risk, as hypoglycaemia may be more problematic when combined with insulin. - Pregnancy and lactation: avoid unless the potential benefit outweighs the risk; discuss with a healthcare professional. - Concomitant insulin or sulfonylureas: monitor for signs of hypoglycaemia and adjust therapy as needed. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Linagliptin can interact with other medicines, and interactions are classified by their clinical significance.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycaemia; dose adjustment may be required. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise linagliptin plasma levels. - Strong P‑glycoprotein inhibitors (e.g., itraconazole): can increase exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism and may reduce linagliptin efficacy. - Thiazide diuretics: may blunt glucose‑lowering effect. - ACE inhibitors or ARBs: monitor blood pressure and renal function when combined. - NSAIDs: may affect renal function, requiring periodic assessment.